Breast Cancer

New data underlines Modrenal's genetic mechanism of action in breast cancer

Published in Cancer Weekly, December 30th, 2003

Bioenvision, Inc., (BIV) has presented new data underlining the ability of its lead breast cancer treatment, Modrenal (trilostane), to suppress the activity of estrogen at two groups of genes involved in breast cancer growth.

The research from Queen Mary, University Of London, and presented for the first time at the 26th San Antonio (Texas) Breast Cancer Symposium, helps to explain reported clinical benefit rates of over 50% and differentiates Modrenal's mechanism of action from existing therapies, such as tamoxifen and the aromatase inhibitors.

In hormone sensitive breast cancer, estrogen affects tumor growth through two main pathways. The preferred...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-12-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry